NEW YORK, July 14, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer’s disease, today announced that it is pleased with the recent press coverage the Company and Dr. Daniel G. Chain, Ph.D., the Company’s Chairman and Chief Executive Officer, recently has received. A number of media outlets increasingly are focusing the attention of their audiences towards Alzheimer’s disease, which has more than 5 million sufferers in the United States, and Dr. Chain’s breakthrough efforts in finding a disease modifying treatment for this devastating, progressive, neurodegenerative and ultimately fatal disease.
